Document is current
Any future updates will be listed below
-
Authors
Griffiths, Gareth O.
FitzGerald, Richard
Jaki, Thomas
Corkhill, Andrea
Reynolds, Helen
Ewings, Sean
Condie, Susannah
Tilt, Emma
Johnson, Lucy
Radford, Mike
Simpson, Catherine
Saunders, Geoffrey
Yeats, Sara
Mozgunov, Pavel
Tansley-Hancock, Olana
Martin, Karen
Downs, Nichola
Eberhart, Izabela
Martin, Jonathan W. B.
Goncalves, Cristiana
Song, Anna
Fletcher, Tom
Byrne, Kelly
Lalloo, David G.
Owen, Andrew
Jacobs, Michael
Walker, Lauren
Lyon, Rebecca
Woods, Christie
Gibney, Jennifer
Chiong, Justin
Chandiwana, Nomathemba
Jacob, Shevin
Lamorde, Mohammed
Orrell, Catherine
Pirmohamed, Munir
Khoo, Saye
,
-
Funding
Funding for this research was provided by:
Cancer Research UK (Core funding Southampton Clinical Trials Unit)
National Institute for Health Research (CTU support funding Southampton Clinical Trials Unit, Royal Liverpool and Broadgreen Clinical Research Facility, BRC-1215-20014, NIHR300576)
Unitaid
United Kingdom Research and Innovation (EP/R024804/1, Core funding)
Wellcome Trust (Core funding)
Medical Research Council (Core funding)
United Kingdom Medical Research Council (MC_UU_00002/14)
- License Information
-
More Information
Article History
Received: 29 March 2021
Accepted: 14 July 2021
First Online: 26 July 2021
Declarations
:
: West Midlands - Edgbaston Research Ethics Committee (REC reference: 20/WM/0136), 12/05/2020, , I certify that this trial has received appropriate ethical approval as described above. We will obtain informed consent from all participants entering into AGILE. If the patient lacks capacity to give consent due to the severity of their medical condition (e.g. patients with WHO Clinical Progression Scale of Grades 7 (hospitalised, intubation and mechanical ventilation, PaO<sub>2</sub>/FiO<sub>2</sub> ≥ 150 or SpO<sub>2</sub>/FiO<sub>2</sub> ≥ 200), 8 (hospitalised mechanical ventilation PaO<sub>2</sub>/FiO<sub>2</sub> < 150 (SpO<sub>2</sub>/FiO<sub>2</sub> < 200) or vasopressors or 9 (hospitalised, mechanical ventilation PaO<sub>2</sub>/FiO<sub>2</sub> < 150 and vasopressors, dialysis or ECMO), then in the first instance, consent may be obtained from the patient’s personal legal representative.
: Not applicable.
: AO is a Director of Tandem Nano Ltd and co-inventor of patents relating to drug delivery. Also unrelated, AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck. MP receives research funding from various organisations including the MRC and NIHR. He has also received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis), a PhD studentship jointly funded by EPSRC and Astra Zeneca and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT (). None of these of funding sources have been used for the current paper.
